Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives

被引:132
作者
Mandel, S [1 ]
Weinreb, O [1 ]
Amit, T [1 ]
Youdim, MBH [1 ]
机构
[1] Technion, Fac Med, Dept Pharmacol, IL-31096 Haifa, Israel
关键词
Parkinson's disease; neuroprotection; rasagiline; propargylamine; ladostigil; PKC; Bcl-2; cell death; MAPK;
D O I
10.1016/j.brainresrev.2004.12.027
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The mitochondria are directly involved in cell survival and death. Drugs that protect mitochondria viability and prevent apoptotic cascade mechanisms involved in mitochondrial permeability transition pore (MPTp) will be cytoprotective. Rasagiline (N-propargyl-1R-aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO) B inhibitor, anti-Parkinson drug. Unlike selegiline, rasagiline is not derived from amphetamine, is not metabolized to neurotoxic I-methamphetamine derivative, nor does it have sympathomimetic activity. Rasagiline is effective as monotherapy or adjunct to L-dopa for patients with early and late Parkinson's disease (PD), and adverse events do not occur with greater frequency in subjects receiving rasagiline than those on placebo. Controlled studies indicate that it might have a disease-modifying effect in PD that may be related to neuroprotection. Its S-isomer, TVP 1022, is a relatively inactive MAO inhibitor. However, both drugs have similar neuroprotective activities in neuronal cell cultures in response to various neurotoxins and in vivo (global ischemia, neurotrauma, head injury, anoxia, etc.), indicating that MAO inhibition is not a pre-requisite for neuroprotection. Structure activity studies have shown that the neuroprotective activity is associated with the propargyl moiety of rasagiline, which protects mitochondrial viability and MPTp by activating Bel-2 and protein kinase C (PKC), and down regulating pro-apoptotic FAS and Bax. Rasagiline and its derivatives also process amyloid precursor protein (APP) to the neuroprotective-neurotrophic soluble APP alpha (sAPP alpha) by PKC and MAP kinase-dependent activation of alpha-secretase. The neuroprotective activity of propargylamine has led us to develop novel bifunctional neuroprotective iron-chelating MAO-inhibiting drugs possessing propargyl moiety for the treatment of other neurodegenerative diseases. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:379 / 387
页数:9
相关论文
共 80 条
[51]   MEMBRANE-ALTERATIONS AS CAUSES OF IMPAIRED SIGNAL-TRANSDUCTION IN ALZHEIMERS-DISEASE AND AGING [J].
ROTH, GS ;
JOSEPH, JA ;
MASON, RP .
TRENDS IN NEUROSCIENCES, 1995, 18 (05) :203-206
[52]   A functional role for mitochondrial protein kinase Cα in Bcl2 phosphorylation and suppression of apoptosis [J].
Ruvolo, PP ;
Deng, XM ;
Carr, BH ;
May, WS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (39) :25436-25442
[53]   Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor [J].
Sagi, Y ;
Weinstock, M ;
Youdim, MBH .
JOURNAL OF NEUROCHEMISTRY, 2003, 86 (02) :290-297
[54]   HYPERACTIVATION OF SIGNAL-TRANSDUCTION SYSTEMS IN ALZHEIMERS-DISEASE [J].
SAITOH, T ;
HORSBURGH, K ;
MASLIAH, E .
ALZHEIMERS DISEASE: AMYLOID PRECUSOR PROTEINS, SIGNAL TRANSDUCTION, AND NEURONAL TRANSPLANTATION, 1993, 695 :34-41
[55]   INCREASED MONOAMINE-OXIDASE-B ACTIVITY IN PLAQUE-ASSOCIATED ASTROCYTES OF ALZHEIMER BRAINS REVEALED BY QUANTITATIVE ENZYME AUTORADIOGRAPHY [J].
SAURA, J ;
LUQUE, JM ;
CESURA, AM ;
DAPRADA, M ;
CHANPALAY, V ;
HUBER, G ;
LOFFLER, J ;
RICHARDS, JG .
NEUROSCIENCE, 1994, 62 (01) :15-30
[56]   ASSESSMENT OF PROTEIN-KINASE-C ISOZYMES BY 2-SITE ENZYME-IMMUNOASSAY IN HUMAN BRAINS AND CHANGES IN ALZHEIMERS-DISEASE [J].
SHIMOHAMA, S ;
NARITA, M ;
MATSUSHIMA, H ;
KUMURA, J ;
KAMEYAMA, M ;
HAGIWARA, M ;
HIDAKA, H ;
TANIGUCHI, T .
NEUROLOGY, 1993, 43 (07) :1407-1413
[57]  
Siderowf A, 2002, ARCH NEUROL-CHICAGO, V59, P1937
[58]  
Siderowf A, 2004, ARCH NEUROL-CHICAGO, V61, P561
[59]  
SLACK BE, 1993, J BIOL CHEM, V268, P21097
[60]   Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease [J].
Sterling, J ;
Herzig, Y ;
Goren, T ;
Finkelstein, N ;
Lerner, D ;
Goldenberg, W ;
Miskolczi, I ;
Molnar, S ;
Rantal, F ;
Tamas, T ;
Toth, G ;
Zagyva, A ;
Zekany, A ;
Lavian, G ;
Gross, A ;
Friedman, R ;
Razin, M ;
Huang, W ;
Krais, B ;
Chorev, M ;
Youdim, MB ;
Weinstock, M .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (24) :5260-5279